Christina Mattina

Diet and wellness impact multiple sclerosis management, enhancing quality of life and reducing fatigue through lifestyle changes and holistic approaches.

Explore how the Veteran Affairs (VA) MS Centers of Excellence enhance veteran care through a hub-and-spoke model, telehealth, and groundbreaking research.

Nurse practitioners play an essential role in diagnosing, treating, and supporting individuals living with Alzheimer disease.

Early intervention and effective therapies are transforming multiple sclerosis management, enhancing patient outcomes, and delaying disability progression.

To mark the 30th anniversary of The American Journal of Managed Care, each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The November issue features a conversation with Laurie C. Zephyrin, MD, MPH, MBA, senior vice president for achieving equitable outcomes at the Commonwealth Fund. This interview has been edited for length and clarity.

Darla Chapman, DNP, ARNP, University of Washington, speaks on the evolution of Alzheimer diagnosis, emphasizing early detection and innovative biomarkers.

Premiums for coverage on the ACA marketplaces are set to jump by an average of 26% next year, even before the expiration of subsidies is factored in.

ACOs serving patients with complex needs are on the rise, but policy changes are needed to support providers treating special populations.

AstraZeneca has struck a deal with the Trump administration to sell lower-priced drugs via TrumpRx, following a similar agreement with Pfizer.

The FDA has approved a second generic version of oral mifepristone, used to terminate pregnancy, after determining it is identical to the branded drug.

To mark the 30th anniversary of The American Journal of Managed Care, each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The October issue features a conversation with Ge Bai, PhD, CPA, professor of accounting at Johns Hopkins Carey Business School and professor of health policy and management at Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland.

There are clear benefits to starting biologic therapy earlier for severe asthma, as well as initiation patterns by ethnicity, according to data at ERS Congress 2025.

Artificial intelligence (AI) holds the potential to democratize precision oncology, but it must be implemented thoughtfully.

In a time of skyrocketing oncology drug costs, the role of pharmacists in managing patients’ treatment and keeping care in the outpatient setting is more urgent than ever.

Panelists discussed the ingredients of successful handoffs at the time of cancer diagnosis and ways to collaborate as screening capabilities evolve.

As therapeutic advances enable patients with cancer to live longer, greater attention is needed to support the goal of survivorship, starting at diagnosis.

Cardiologists, nephrologists, and payers met in Scottsdale, Arizona, on August 26, 2025, to share insights on how team members can work together, empowered by data, to achieve value-based management of cardio-renal-metabolic syndrome.

In 2025, each issue of Population Health, Equity & Outcomes will feature a profile of a health system leader transforming care in their area of expertise. This issue spotlights a conversation with Marisa Rogers, MD, MPH, chief medical officer at Oak Street Health.

To mark the 30th anniversary of The American Journal of Managed Care, each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The September issue features a conversation with Dora Hughes, MD, MPH, chief medical officer and director of the Center for Clinical Standards and Quality at CMS.

To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The August issue features a conversation with Charles N. (Chip) Kahn III, MPH, the president and CEO of the Federation of American Hospitals and a longtime member of the AJMC editorial board.

To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The July issue features a conversation with David J. Shulkin, MD, a physician and former secretary of the US Department of Veterans Affairs.

In 2025, each issue of Population Health, Equity & Outcomes will feature a profile of a health system leader transforming care in their area of expertise. This issue spotlights a conversation with Ken Cohen, MD, executive director of translational research at Optum Health.

Sessions and posters at the 2025 European Hematology Association Congress evaluated the potential and real-world practices of using artificial intelligence (AI) to predict and improve outcomes for patients with hematological diseases.

The late-breaking abstracts presented on the last day of the 2025 European Hematology Association (EHA) Congress show “what a vibrant clinical specialty we’re in,” according to session cochair Brian Huntly, PhD.

Adolescent and young adult (AYA) patients with hematological diseases have unique needs that require a multidisciplinary strategy to ensure their mental and sexual well-being during and beyond treatment, clinicians and patients agreed.

Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.

Our knowledge of the effects of space and low gravity on blood cells, clotting, and anemia continues to expand, but further research is needed as commercial spaceflights are poised to grow in popularity.

A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.

Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in the European context, but panelists explained the next steps that are required to advance the use of MRD.

The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.